Search Within

Heiko Schoder

  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (76)
  2. Meeting Abstract (72)
  3. Research Letter (4)
  4. Review (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Molecular Imaging and Therapy Service (153)
  4. Radiology, Department of (153)
  5. Center for Hematologic Malignancies (135)
  6. Lymphoma (128)

More Groups

People
  1. Andrew Zelenetz (66)
  2. Alison Moskowitz (59)
  3. David Straus (56)
  4. Ariela Noy (55)
  5. Maria Palomba (53)
  6. Paul Hamlin (51)

More People

Years
  1. 2025 (6)
  2. 2024 (13)
  3. 2023 (18)
  4. 2022 (7)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Blood (49)
  2. Journal of Clinical Oncology (21)
  3. Hematological Oncology (11)
  4. Blood Advances (6)
  5. Journal of Nuclear Medicine (6)
  6. European Journal of Nuclear Medicine and Molecular Imaging (5)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. American Society of Clinical Oncology (21)
  3. Wiley Blackwell (14)
  4. Springer (8)
  5. Elsevier Inc. (6)
  6. Nature Publishing Group (6)

More Publishers

Results (153)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL
    Meeting Abstract

    Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schöder, H.; Jung, S. H.; Popplewell, L.; Chang, J. E.; Moskowitz, C.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Metabolic tumor volume in lymphoma: Hype or hope?
    Journal Article

    Schöder, H.; Moskowitz, C.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
    Journal Article

    Shoushtari, A. N.; Ong, L. T.; Schoder, H.; Singh-Kandah, S.; Abbate, K. T.; Postow, M. A.; Callahan, M. K.; Wolchok, J.; Chapman, P. B.; Panageas, K. S.; more...
    Melanoma Research (2016)

    Fulltext@MSK | Save
  • US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816
    Journal Article

    Press, O. W.; Li, H.; Schöder, H.; Straus, D. J.; Moskowitz, C. H.; LeBlanc, M.; Rimsza, L. M.; Bartlett, N. L.; Evens, A. M.; Mittra, E. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
    Journal Article

    Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D. J.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schoder, H.; Jung, S. H.; Popplewell, L. L.; Chang, J. E.; Moskowitz, C. H.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save